KR102467968B1 - 베타-락타마제 제형 및 이의 용도 - Google Patents

베타-락타마제 제형 및 이의 용도 Download PDF

Info

Publication number
KR102467968B1
KR102467968B1 KR1020177012353A KR20177012353A KR102467968B1 KR 102467968 B1 KR102467968 B1 KR 102467968B1 KR 1020177012353 A KR1020177012353 A KR 1020177012353A KR 20177012353 A KR20177012353 A KR 20177012353A KR 102467968 B1 KR102467968 B1 KR 102467968B1
Authority
KR
South Korea
Prior art keywords
beta
lactamase
weight
release
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012353A
Other languages
English (en)
Korean (ko)
Other versions
KR20170065649A (ko
Inventor
앤드류 브리스톨
마이클 카레코
쉴라 코넬리
Original Assignee
신세틱 바이오로직스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신세틱 바이오로직스, 인코퍼레이티드 filed Critical 신세틱 바이오로직스, 인코퍼레이티드
Publication of KR20170065649A publication Critical patent/KR20170065649A/ko
Application granted granted Critical
Publication of KR102467968B1 publication Critical patent/KR102467968B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020177012353A 2014-10-08 2015-10-08 베타-락타마제 제형 및 이의 용도 Active KR102467968B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462061507P 2014-10-08 2014-10-08
US62/061,507 2014-10-08
US201562126556P 2015-02-28 2015-02-28
US62/126,556 2015-02-28
US201562205443P 2015-08-14 2015-08-14
US62/205,443 2015-08-14
PCT/US2015/054606 WO2016057744A1 (en) 2014-10-08 2015-10-08 Beta-lactamase formulations and uses thereof

Publications (2)

Publication Number Publication Date
KR20170065649A KR20170065649A (ko) 2017-06-13
KR102467968B1 true KR102467968B1 (ko) 2022-11-16

Family

ID=55653744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012353A Active KR102467968B1 (ko) 2014-10-08 2015-10-08 베타-락타마제 제형 및 이의 용도

Country Status (10)

Country Link
US (3) US10105322B2 (enExample)
EP (1) EP3204495B1 (enExample)
JP (1) JP6672277B2 (enExample)
KR (1) KR102467968B1 (enExample)
CN (1) CN107148473B (enExample)
AU (1) AU2015330937B2 (enExample)
CA (1) CA2962959C (enExample)
ES (1) ES2806426T3 (enExample)
MX (1) MX2017004473A (enExample)
WO (1) WO2016057744A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
WO2016105498A1 (en) 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
WO2016137993A1 (en) 2015-02-23 2016-09-01 Synthetic Biologics, Inc. Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
KR20170122776A (ko) 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
CN109562147B (zh) * 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
US20190275120A1 (en) * 2016-11-01 2019-09-12 Synthetic Biologics, Inc. Methods and compositions for attenuating antibiotic resistance
SG10201609137PA (en) * 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Gamma-polyglutamic acid and zinc compositions
US20200108130A1 (en) * 2017-03-21 2020-04-09 Synthetic Biologics, Inc. Beta-lactamase formulations
KR20200074982A (ko) * 2017-10-25 2020-06-25 다 볼떼라 베타-락타마아제 변이체
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN112689506A (zh) * 2018-08-05 2021-04-20 达·沃尔泰拉公司 用于治疗移植物抗宿主疾病的组合物
US20220218800A1 (en) * 2019-05-06 2022-07-14 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
CN115298702A (zh) * 2020-03-10 2022-11-04 Ai:On创新公司 用于哺乳动物迁移学习的系统和方法
CN112137984B (zh) * 2020-10-30 2023-02-03 四川制药制剂有限公司 头孢克洛胶囊及其制备工艺
WO2023168316A1 (en) * 2022-03-04 2023-09-07 Michael Ogburn Enteric coated dry powdered cannabinoid formulations
CN116790567A (zh) * 2022-12-30 2023-09-22 扬州大学 来源于土壤宏基因组的β-内酰胺酶及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148041A1 (en) * 2010-05-24 2011-12-01 Prevab R Llc Modified beta-lactamases and methods and uses related thereto

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL89987C (enExample) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
JP2813809B2 (ja) * 1989-06-19 1998-10-22 武田薬品工業株式会社 有核顆粒製剤およびその製造法
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
JPH08143476A (ja) * 1994-11-18 1996-06-04 Japan Tobacco Inc 薬物放出制御膜及び固形製剤
CN1190434A (zh) 1995-07-07 1998-08-12 诺沃挪第克公司 用不能形成芽孢的芽孢杆菌生产蛋白质的方法
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
ATE481090T1 (de) * 1998-07-28 2010-10-15 Takeda Pharmaceutical Leicht zerfallende feste zubereitung
FI4533U1 (fi) * 2000-03-14 2000-08-10 Finnzymes Oy Entsyymikoostumus maidon käsittelemiseksi
US7585674B2 (en) 2001-05-29 2009-09-08 Kao Corporation Host microorganisms
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
WO2006122835A1 (en) 2005-05-18 2006-11-23 Da Volterra Colonic delivery of adsorbents
EP1993518A4 (en) * 2006-03-06 2012-12-12 Pozen Inc DOSAGE FORMS FOR THE ADMINISTRATION OF MEDICINAL COMBINATIONS
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
US8273376B2 (en) * 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
JP2013525488A (ja) * 2010-05-03 2013-06-20 アプタリス ファーマ リミテッド 消化酵素混合物を含有するパンクレアチンを含むマイクロペレット組成物
WO2013015388A1 (ja) * 2011-07-26 2013-01-31 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｎｄｍ阻害剤
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
KR101952478B1 (ko) * 2011-11-30 2019-02-26 다케다 야쿠힌 고교 가부시키가이샤 유핵정
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US9290754B2 (en) * 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
WO2016105498A1 (en) * 2014-12-23 2016-06-30 Synthetic Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
KR20170122776A (ko) * 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148041A1 (en) * 2010-05-24 2011-12-01 Prevab R Llc Modified beta-lactamases and methods and uses related thereto

Also Published As

Publication number Publication date
CA2962959A1 (en) 2016-04-14
JP6672277B2 (ja) 2020-04-01
CA2962959C (en) 2023-04-04
JP2017535521A (ja) 2017-11-30
AU2015330937A1 (en) 2017-05-25
US10105322B2 (en) 2018-10-23
EP3204495A4 (en) 2018-04-18
EP3204495B1 (en) 2020-04-22
AU2015330937B2 (en) 2021-07-15
US20160101058A1 (en) 2016-04-14
EP3204495A1 (en) 2017-08-16
MX2017004473A (es) 2017-10-12
ES2806426T3 (es) 2021-02-17
KR20170065649A (ko) 2017-06-13
US20180360762A1 (en) 2018-12-20
US20210007994A1 (en) 2021-01-14
US12178917B2 (en) 2024-12-31
US10828260B2 (en) 2020-11-10
WO2016057744A1 (en) 2016-04-14
CN107148473B (zh) 2021-08-06
CN107148473A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
KR102467968B1 (ko) 베타-락타마제 제형 및 이의 용도
JP7530933B2 (ja) 経口抗生物質からのマイクロバイオーム防御
US11944669B2 (en) Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
US20200108130A1 (en) Beta-lactamase formulations
HK1241918B (en) Beta-lactamase formulations and uses thereof
HK1241918A1 (en) Beta-lactamase formulations and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4